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ABSTRACT
Aims p16(INK4a) is an important factor in
carcinogenesis, and its expression is linked to oncogene-
induced senescence. Very recently it was shown that
upregulation and downregulation of p16 indicates a
senescence barrier in the serrated route of colorectal
cancer. However, in soft tissue sarcoma (STS), the
senescence mechanism is still not understood. In this
study, we analysed a well characterised cohort of STS for
p16(INK4a) expression and correlated the results with
clinicopathological parameters including survival.
Methods Tissue microarrays (TMA) of 183 soft tissue
and bone tumours were analysed immunohistochemically.
Furthermore, mRNA expression of p16(INK4a) was
evaluated in four sarcoma cell lines, and a demethylation
test was performed by treatment with 5-aza-20-
deoxycytide.
Results On protein level, expression of p16(INK4a) was
observed in undifferentiated pleomorphic sarcoma (UPS)
in 69.1%, leiomyosarcoma in 85.7%, synovial sarcoma in
77.8%, liposarcoma in 88.9%, angiosarcoma in 60.9%
and MPNST in 22.2%. Loss of p16(INK4a) was observed
in high grade sarcomas and showed a significant
correlation with reduced patient survival (p=0.032). On
DNA level, one out of four sarcoma cell lines exhibited a
methylated p16(INK4a) promoter analysed by
methylation-specific PCR. p16(INK4a) mRNA and protein
expression was restored after demethylation using 5-aza-
20-deoxycytide.
Conclusions Upregulation of p16(INK4a) might be
associated with the induction of senescence and indicates
a senescence barrier. Downregulation of p16(INK4a) is
found in malignant progression, and is significantly
correlated with reduced patient survival. Downregulation
of p16(INK4a) may be explained by DNA-
hypermethylation in sarcoma cells.
INTRODUCTION
Soft tissue sarcomas (STS) are a rare, heterogeneous
and highly malignant group of tumours originating
from the mesenchymal lineage. Local recurrence is
common (20%), and metastases occur in one-third
of the patients.1 2 Prognostic and predictive
markers in potentially curable STS should guide
therapy after surgical resection. Neoadjuvant
therapy is used with increasing frequency and may
improve prognosis in high-risk cases. The indica-
tion for adjuvant chemotherapy for high-risk
patients is still under debate, therefore, new diag-
nostic, predictive and prognostic biomarkers are
needed.3 These biomarkers should support the clin-
ical treatment of the neoplastic process, for
example, by selecting specific drug regiments.
p16(INK4a) is a cell-cycle inhibitor and an
important factor in carcinogenesis. It controls
p16INK4a—dependent growth arrest and its
expression can be linked to oncogene-induced sen-
escence.4–6 Oncogene-induced senescence is charac-
terised by an irreversible growth arrest and occurs as
a consequence of oncogene activation. The abrup-
tion of oncogene-induced senescence is an import-
ant mechanism for malignant transformation and
can be caused by genetic alterations leading to a loss
of function of p16(INK4a). The induction of p16
(INK4a) in premalignant lesions, and its loss during
malignant transformation, have been demonstrated
in the carcinogenesis of the liver, lung and pan-
creas.7–9 Loss of p16(INK4a) is often caused by
CDKN2A p16(INK4a) promoter hypermethyla-
tion.10 However, in sarcoma genesis, the senescence
mechanism is still not understood and has not been
described before. In our previous studies, we
showed that upregulation and downregulation of
p16(INK4a) expression in BRAF-mutated polyps/
adenomas indicates a senescence barrier in the ser-
rated route to colonic cancer.6 In this study, we
expanded the analysis to different types of sarcomas
in order to explore mechanisms of senescence and
to find associations with clinicopathological para-
meters that may be important for tumour progres-
sion and survival. We analysed the expression of
p16(INK4a) in a well-characterised cohort of sarco-
mas, and investigated the methylation status of the
p16(INK4a) promoter in cell lines representing dif-
ferent sarcoma types.
Our objectives in this study were (1) to evaluate
the p16(INK4a) expression status in a series of well-
characterised sarcomas on protein level, (2) to cor-
relate the expression with clinicopathological data
including patient survival, and (3) to analyse the
methylation status in sarcoma cell lines to detect
potential pathomechanisms in sarcomagenesis.
MATERIALS AND METHODS
Patients
TMAs containing samples from 183 patients were
constructed. Tissue samples mostly originated from
surgical specimens of patients diagnosed and
treated from 1989 to 2012 in the Sarcoma Centre
at Ludwig-Maximilians University, Munich. Data
on clinical parameters, including sex, age and
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primary site were extracted from the pathologists` original
reports and the database of (ClinicalTrials.gov), number NCT
00003052.11 In addition to the original pathology reports,
microscopic findings (tumour type, according to current WHO
classification and degree of differentiation) were reassessed by
two authors (EK and TK). Nearly all patients underwent surgi-
cal resection of the tumour, and all but 18 (9, 8%) patients had
additional radiotherapy. The patients’ age at the time of diagno-
sis ranged from 19 to 81 years (median age 54 years, female
n=101, male n=82). The sarcomas were located in the extrem-
ities in 60, and in non-extremities in 123 cases.
Tissue microarray construction
The sarcoma TMAs were assembled using 0.6 mm punch biop-
sies in duplicate from all 183 samples according to standard
procedure.12 Totally, 183 specimens of sarcoma tissue were
evaluated.
Immunhistochemistry
Immunohistochemical staining was done on 5 μm tissue sections
of formalin-fixed paraffin-embedded tumour samples. As
primary antibodies, anti-p16Ink4a mouse monoclonal antibody
(Diagnostic Biosystems, dilution 1 : 100) was used. Staining was
performed on a Ventana Benchmark XT autostainer with the
XT ultraView DAB Kit (Ventana Medical Systems). All slides
were counterstained with Haematoxylin (Vector). To exclude
unspecific staining, system controls were included. As positive
controls for the immunohistochemistry, cervical intraepithelial
neoplasia (p16INK4a) was used. The immunostaining of the
cells was evaluated and scored semiquantitatively: 0, negative; 1,
weak; 2, moderate and 3, strongly positive.
Statistical analysis
Follow-up was performed in outpatient clinics or by contacting
the patients’ general practitioners, and data were updated until
September 2012. Survival was calculated from the date of first
diagnosis. Statistical analyses were performed by SPSS 20.0
(SPSS, Chicago, IL) software. Survival curves were calculated by
the Kaplan–Meier method. The log rank test was used to assess
differences in survival. The HRs are given with CIs for each
factor.
Cell lines and treatment
Human sarcoma cell lines SW872 and SW982 were grown in
DMEM (Invitrogen) supplemented with 5% FCS. The human
sarcoma cell line SKUT1 was kept in MEM supplemented with
10% FCS, 1% NEAA and 1% L-Glutamine. Human sarcoma
cell line U2OS was kept in DMEM supplemented with 10%
FCS. All cells were incubated at 5% CO2 according to standard
procedures.
U2OS cells were treated by adding the de-methylating agent
5-aza-20deoxycytidine (5-Aza, Sigma) for 72 h to the medium.
Different concentrations (0, 1 and 10 mM) were tested.
DNA isolation and bisulfite treatment
Genomic DNA was isolated using the DNeasy Blood & Tissue
Kit (Qiagen) according to the manufacturer’s instructions.
Subsequently, 500 ng of DNA was treated with bisulphite using
the EZ DNA Methylation Kit (Zymo Research).
Methylation specific PCR (MSP)
Methylation-specific PCR analyses were carried out in a total
volume of 20 ml using 1.5 units Platinum Taq-polymerase
(Invitrogen) per reaction, and ∼50 ng of bisulphite converted
DNA as template. The reaction conditions were the following:
95°C for 5 min, followed by 35 cycles of 95°C for 30 s, 65°C
for 30 s and 72°C for 30 s. The final elongation step was per-
formed for 7 min at 72°C. The oligonucleotide sequences used
for the MSP are the following:
p16M fwd: 50-TTATTAGAGGGTGGGGCGGATCGC-30;
p16M rev: 50-GACCCCGAACCGCGACCGTAA -30;
p16U fwd: 50- TTATTAGAGGGTGGGGTGGATTGT -30;
p16U rev: 50- CAACCCCAAACCACAACCATAA -30.
Amplified fragments (M=150 bp, U=151 bp) were separated
by electrophoresis on 10% polyacrylamide gels, and visualised
by staining with ethidium bromide. Pictures were taken using a
MultiImage Light Cabinet (Alpha Innotech).
Western blot analysis
SDS-PAGE and western blotting were performed according to
standard protocols. Cells were lysed in RIPA lysis buffer (50 mM
Tris/HCl, pH 8.0, 250 mM NaCl, 1% NP40, 0.5% (w/v) sodium
deoxycholate, 0.1% sodium dodecylsulfate, and complete mini
protease inhibitor tablets (Roche)). Lysates were sonicated and
centrifuged at 16.060 g for 15 min at 4°C. Per lane, 60 mg of
whole cell lysate was separated using a 12% SDS-acrylamide gel
and transferred on Immobilon PVDF membranes (Millipore).
ECL signals were recorded using a CF440 Imager (Kodak).
Antibodies were the following:
α-tubulin: monoclonal anti-α-tubulin, clone DM1A (Sigma)
p16: monoclonal (F-12) p16 antibody, (Santa Cruz)
Quantitative real-time PCR
Total RNA was prepared with the High Pure RNA Isolation Kit
(Roche) according to the manufacturer’s instructions. cDNAwas
generated from 1 mg of total RNA per sample using anchored
oligo(dT) primers (Verso Kit). RT-qPCR was performed by
using the LightCycler 480 (Roche) and the Fast SYBR Green
Master Mix (Applied Biosystems). Only primer pairs resulting in
a single peak in the melting curve analysis were used. The
qPCR-primers used in this study were the following:
GAPDH qPCR fwd: 50- GCTCTCTGCTCCTCCTGTTC-3‘;
GAPDH qPCR rev: 50- ACGACCAAATCCGTTGACTC-3;
p16 qPCR fwd: 50- CAACGCACCGAATAGTTACG-3;
p16 qPCR rev: 50- CTGCCCATCATCATGACCTGG-3;
RESULTS
Immunohistochemistry
The results of the entire tumour collective are summarised in
table 1. The expression was scored semiquantitatively by a 4-tier
scale (0: negative; 1: weak; 2: moderate; 3: strongly positive;
figure 1) that was reduced to a 2-tier system (0: negative; vs 1/2/3:
positive) for statistical analysis. On protein level, positive expres-
sion was observed in 136 (74.3%) specimens. In detail, the ratio of
positive expression according to the different tumour types is
given in table 1.
Immunohistochemistry and clinicopathological parameters
Percentages of positive expression were calculated for age, sex
and tumour site (extremities vs non-extremities); 70% (0.5886;
0.7842) of male specimens and 78% (0.6922; 0.8515) of
female specimens showed positive staining with p16. No statis-
tical significant correlation with protein expression could be
demonstrated.
Grade 1, grade 2 and grade 3 tumours were observed in
3.3%, 34.4% and 62.3%, respectively. 100% (0.4385; 1) of
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grade 1 tumours showed positive expression of p16. In grade 2
and grade 3 tumours, nearly equal percentages of positive stain-
ing 78.0% (0.6476; 0.8725) vs 74.7% (0.6379; 0.8314)) were
observed.
Survival analysis
At the time of last follow-up, 70 patients were dead and 113
were alive. The median survival time for the whole group was
77 (41; 99) months, with a 5-year and 10-year survival rate of
56% and 46%, respectively.
High-grade tumours were subdivided according to tumour
type. Survival was calculated for groups containing at least 15
patients; 10-year survival rates were similar for liposarcomas,
leiomyosarcomas, synovial sarcoma and UPS (60%, 55%, 54%,
and 43%, respectively), but statistically significantly lower for
angiosarcomas (11%, figure 2).
Kaplan–Meier analysis of all patients showed a significantly
higher survival rate for p16-positive tumours compared to
p16-negative specimens (p=0.032). The same result was seen
for leiomyosarcomas, liposarcomas and synovial sarcomas. No
statistical significant difference in survival rates depending on
p16 expression was seen in UPS and angiosarcomas (table 2).
Investigation of the p16 methylation status in sarcoma
cell lines
The methylation status of p16(INK4a) promotor was analysed
in the sarcoma cell lines SW872 (liposarcoma), SW982 (synovial
sarcoma), SKUT1 (leiomyosarcoma) and U2OS (osteosarcoma).
For this, genomic DNA was isolated, treated with bisulphite and
applied as template for subsequent methylation-specific PCR
(MSP). While the MSP for SKUT1 cells did not result in a
detectable product, SW872 and SW982 showed a band for
unmethylated p16, whereas for U2OS cells, a band representing
methylated p16 was observed (figure 3A). Water was used in a
non-template negative control, and gDNA of the colorectal
cancer cell line HCT116 was used as positive control.
Table 1 Expression of p16 according to the different entities
Entity All
P 16 positive
n % 95% CI
UPS 55 38 69.1 (0.5597 to 0.7972)
Leiomyosarcoma 35 30 85.7 (0.7062 to 0.9374)
Liposarcoma 27 24 88.9 (0.7194 to 0.9615)
Angiosarcoma 23 14 60.9 (0.4079 to 0.7784)
Synovialsarcoma 18 14 77.8 (0.5478 to 0.91)
MPNST 9 2 22.2 (0.0632 to 0.5474)
Carcinosarcoma 4 4 100 (0.5101 to 1)
Chondrosarcoma 3 2 67 (0.2077 to 0.9385)
Rhabdomyosarcoma 3 3 100 (0.4385 to 1)
Malignant SFT 2 2 100 (0.3424 to 1)
Alveolar soft tissue sarcoma 2 2 100 (0.3424 to 1)
Myxofibrosarcoma 2 1 50 (0.0945 to 0.9055)
All patients 183 136 74.3 (0.6753 to 0.801)
Figure 1 Examples of the immunohistochemical assessment of p16(INK4a) staining in sarcomas. Negative staining of tumour cells (0), weakly
positive (1), moderately positive (2), strongly positive (3) (10×magnification, insert: 40×magnification, nuclear and cytoplasmatic staining).
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In order to test whether this methylation was reversible upon
use of a demethylating agent, we exposed U2OS cells to differ-
ent concentrations of the pharmacological substance 5-aza-
20deoxycytidine (5-Aza). Indeed, following treatment with 1, 10
or 50 mM 5-Aza for 72 h, a band for unmethylated p16 was
restored, as shown by MSP (figure 3B). To test, whether
demethylation of the gene resulted in an increased expression of
the p16 mRNA, we isolated RNA from cells treated with
10 mM 5-Aza, or left untreated, and included the RNA of the
cervix carcinoma cell line HeLa as a positive control. While no
p16 was detectable in untreated U2OS cells, expression was sig-
nificantly induced upon treatment (figure 3C).
Figure 2 Univariate analysis (log-rank test, Kaplan–Meier curves) (A) of the different sarcoma entities and (B) expression of p16(INK4a) with
observed survival (p=0.032).
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To prove that the increase of p16 mRNA went along with a
higher expression on the protein level, U2OS cells, treated for
72 h using different 5-Aza concentrations, were lysed and sub-
jected to western blot. This revealed a dose-dependent increase
of p16 protein, indicating that this effect was mediated by the
demethylation of the p16 gene (figure 3D).
DISCUSSION
This study demonstrates the absence of p16(INK4a) expression
in a subgroup of high-grade sarcomas with a very aggressive
malignant potential in a well-characterised cohort of 183 soft
tissue and bone sarcomas. To our knowledge, this is the first
study to show that the absence of p16(INK4a) expression corre-
lates with reduced patient survival in sarcomas. This is particu-
larly evident in oncogene/translocation-associated sarcomas, for
example, dedifferentiated liposarcomas and synovial sarcomas
(p<0.001 and p=0.010, respectively), indicating an upregula-
tion of p16(INK4a) in the initial phase of tumour progression
Table 2 Differences in observed survival depending on expression
of p16 (HR, CI=95%CI)
Entity Patients HR 95% CI p Value
All 183 1.654 1.028 to 2.660 0.038
UPS 55 0.452 0.273 to 1.784 0.452
Leiomyosarcoma 35 4.466 1.270 to 15.703 0.020
Liposarcoma 27 5.908 1.502 to 23.234 0.011
Angiosarcoma 23 1.648 0.558 to 4.869 0.366





malignant SFT* 2 –
Alveolar soft tissue sarcoma* 2 –
Myxofibrosarcoma* 2 –
*Number of patients too small for Kaplan–Meier analysis.
Figure 3 The p16(INK4a) promoter is
methylated in U2OS cells: (A) MSP
analysis of the p16 promoter in
different sarcoma cell lines. M and U
represent methylated or unmethylated
alleles, respectively. Water was used as
template for technical negative control
reaction and (bisulphite treated) DNA
from the colorectal cancer cell line
HCT116 as positive control for both
primer sets. (B) MSP analysis of the
p16 promoter in U2OS cells following
treatment with different 5-Aza
concentrations for 72 h. (C) qPCR
analysis for the detection of p16
mRNA upon treatment with 5-Aza,
results were normalised to GAPDH
mRNA. p16 mRNA levels of the cervix
carcinoma cell line HeLa served as a
positive control. Data are represented
as mean±SD (n=3). (D) Western blot
analysis of p16 protein levels in U2OS
cells treated for 72 using different
5-Aza concentrations. α-tubulin served
as a loading control.
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as a senescence barrier, and a loss of p16(INK4a) expression in
the final phase of tumour progression.
Our observations are in concordance with investigations con-
cerning human naevi where the concept of oncogene-induced sen-
escence (OIS) has been established.6 13 In melanocytic naevi, a
stop of cell proliferation is correlated with a high p16INK4a
expression and frequently found in combination with mutations in
the BRAF oncogene. In the model proposed by Michaloglou
et al,13 BRAF-signaling primarily prompts benign naevi to exhibit
a limited growth due to an induction of senescence. This senes-
cence barrier must be overcome by further genetic alterations in
order to lead to the development of malignant melanoma.
Previously, we showed that upregulation and downregulation of
p16(INK4a) in BRAF-mutated polyps/adenomas indicated a senes-
cence barrier in the serrated route of colonic cancer.6 In this study,
we expanded the analysis to mesenchymal neoplasms. Our data
indicate an analogous process in human sarcomas where
oncogene-induced senescence driven by initiating amplifications
or translocations of distinct sarcoma types might cause a growth
arrest and stop further malignant transformation. The loss of p16
(INK4a) expression might overrun the senescence barrier and
could enable further progression into a very aggressive malignant
subtype of sarcoma (figure 4).
We observed p16(INK4a) expression in liposarcoma (88.9%),
leiomyosarcoma (85.7%), synovial sarcoma (77.8%), undifferen-
tiated pleomorphic sarcoma (UPS) (69.1%), and angiosarcoma
(60.9%). However, in UPS and in angiosarcomas, no correlation
between p16(INK4a) expression and observed survival was
noted. This is in concordance with the theory that undifferenti-
ated tumours have such a complex and disturbed karyotype and/
or protein pattern, that no regulated pathways exist. The senes-
cence mechanism might not depend on regulated pathways in
these kinds of tumours, and the regulation of the cell interaction
might be highly disconnected and chaotic. On the other hand,
the so-called oncogene or translocation-depending sarcomas
have regulated pathways in tumour progression at least in the
early phase of malignant transformation with robust biomarkers.
Interestingly, p16(INK4a) expression was very recently described
as a robust diagnostic biomarker for well-differentiated liposarco-
mas (WDLS) distinguishing WDLS from lipomas in combination
or alone with the immunohistochemical markers MDM2 and
CDK4.14 15 Our results confirm these findings, all WDLS show a
senescence-induced high p16(INK4a) expression. Furthermore,
high expression of p16(INK4a) is an interesting diagnostic bio-
marker in leiomyosarcomas that has not been described before.
However, further studies are needed to confirm these findings.
Demethylation tests with p16(INK4a) in four sarcoma cell lines
demonstrated that on mRNA level, two out of four cell lines
showed expression of p16(INK4a). In one remaining sarcoma cell
line, p16(INK4a) expression could be restored after a
demethylation test. This in vitro study showed that downregula-
tion of p16(INK4a) may be explained by DNA hypermethylation
in sarcoma cells. This is in concordance with earlier studies and
might be at least one potential pathomechanism of the absence for
p16(INK4a). However, alternative mechanisms do exist. The cell
line, SK-UT1, showed no methylated or unmethylated alleles, and
may have undergone a deletion of the gene as one possible alterna-
tive mechanism to silence the p16(INK4a) expression.
p16(INK4a) Is an inhibitor of the cyclin-dependent kinases
(CDK), which phosphorylate the retinoblastoma (Rb) protein, a
classic tumour suppressor and key component of the G1/S
checkpoint. Interestingly, very recently, Dickson et al16 pub-
lished a phase II trial of the CDK4 inhibitor, PD0332991, in
patients with an advanced CDK4-amplified well-differentiated
or dedifferentiated liposarcoma. The selective cyclin-dependent
kinase 4 (CDK4)/CDK6 inhibitor PD0332991 inhibits growth
and induces senescence in cell lines and xenografts. Dickson
et al were able to demonstrate that treatment with a CDK4
inhibitor was associated with a favourable progression-free sur-
vival rate in patients with CDK4-amplified and RB-expressing
WDLS/DDLS who had experienced progressive disease despite
standard systemic therapy. Since p16(INK4a) is also a CDK4
inhibitor, these observations are in line with our results and
according to our observations, CDK4 inhibitors obviously
induce senescence in adipocytic differentiated tumours, and also
in other mesenchymal-malignant neoplasms.
In conclusion, we illustrate in this study that upregulation of
p16(INK4a) is associated with the induction of oncogene-induced
senescence, and indicates a senescence barrier. Downregulation of
p16(INK4a) is significantly correlated with reduced patient sur-
vival in dedifferentiated liposarcomas, synovial sarcomas and leio-
myosarcomas and one possible mechanism is epigenetic silencing
through aberrant methylation of the CDKN2A promotor. Further
studies are needed to explore the functional role of p16(INK4a)
and other cell-cycle regulators in the genesis of mesenchymal neo-
plasia. CDK inhibitor therapy might be a promising avenue to
treat patients with these subtypes of sarcomas.
Take home messages
▸ p16(INK4a) is upregulated in sarcomas, and shows a distinct
expression pattern in distinct subgroups.
▸ Reduced expression of p16(INK4a) is significantly associated
with shorter patients survival in sarcomas.
▸ p16(INK4a)-negative sarcomas might indicate a tumour
subgroup eligible for a more aggressive treatment.
▸ Downregulation of p16(INK4a) could be explained by DNA
hypermethylation.
Figure 4 Modell of oncogene-
induced senescence (OIS) in
liposarcoma genesis. In human
liposarcomas high p16(INK4a)
expression is found in well-
differentiated liposarcomas (WDLS)
induced by initiated MDM2/CDK4
amplification indicating a senescence
barrier. Loss of p16(INK4a) is observed
in a subgroup of dedifferentiated
liposarcomas in the final phase of
tumour progression with significantly
reduced patient survival.
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